Skip to content

Earnings call

Lupin Q3 FY26 earnings call

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Other Developed markets constitute around 11% of total sales, and their share is expected to increase with the anticipated closure of the VISUfarma acquisition during this quarter. The company has filed both the injectable generic version and a 505(b)(2) version of Dalbavancin. The company reported 14 consecutive quarters of year-over-year growth as of Q3 FY26. The company says competitors in Tolvaptan are likely to enter in a staggered manner; other competitors have November’26, 30 months stay date and into '27. The company had over 50 active products in its pipeline, with near-term emphasis on Respiratory, Complex Injectables and Biosimilars.

The numbers management gave

Results

  • The company reported 14 consecutive quarters of year-over-year growth as of Q3 FY26.
    Show source
    This marks our 14th consecutive quarter of YoY growth.
  • India revenues grew 5.6% year over year in Q3 FY26, with core prescription business growth of 10.9% partially offset by lower local tender sales in its Global Institutional Business.
    Show source
    Revenues grew 5.6% YoY, with the core prescription business growing 10.9% partially offset by lower local tender sales in our Global Institutional Business.
  • India prescription business grew 9.4% in the nine-month period, broadly in line with IPM growth of 9.3%.
    Show source
    On a nine-month basis, prescription growth stood at 9.4%, broadly in line with IPM growth of 9.3%.
  • Volume growth was 5.6% in Q3 FY26, and the Chronic segment accounted for 67% of its portfolio, up from 65% last quarter. Lupin Limited's Chronic share increased to 67% from 65% in Q2, and in-licensed products accounted for 6% compared with around 12% in FY25, which the company said would positively affect profitability going ahead. Lupin's chronic share has gone up to 67%.
    Show source
    Chronic share has increased to 67% from the 65% levels in Q2 and share of in-licensed products is only 6% as compared to around 12% in FY25, which also has a positive impact on our profitability going ahead .
  • Cardiac and Respiratory therapies grew at 1.3 times and 1.6 times their respective market growth in Q3 FY26.
    Show source
    Both Cardiac and Respiratory therapies continued their strong momentum, growing at 1.3 times and 1.6 times their respective market growth.
  • Other Developed markets, Europe, Canada and Australia, accounted for 11% of total sales and delivered 11% year-over-year growth in Q3 FY26. Lupin Limited's Other Developed markets, including Europe, Canada and Australia, generated INR 812 crores in revenue, representing 11% year-over-year growth.
    Show source
    Page 4 of 18 February 13, 2026 Other Developed Markets As far as Other Developed markets are concerned, which includes markets in Europe, Canada and Australia, revenues in these geographies was INR 812 crores, representing a growth of 11% YoY.
Show 21 more statements

Results

  • Emerging markets grew 42% year over year, with strong growth in Brazil, Mexico and Philippines offsetting tempered performance in South Africa.
    Show source
    Emerging markets delivered an impressive 42% YoY growth, led by Brazil, Mexico and Philippines.
  • Brazil business grew 99% year over year in local currency in Q3 FY26, driven by successful commercialization of Dapagliflozin.
    Show source
    Brazil in particular maintained strong momentum post the turnaround last quarter, growing 99% YoY in local currency, driven by successful commercialization of Dapagliflozin.
  • R&D spend was 7.5% of sales in Q3 FY26.
    Show source
    On R&D, spend was 7.5% of sales this quarter, a mong the highest in the Indian Pharma sector, ref lecting our continued focus on Complex and S pecialty platforms.
  • Normalizing the loss of exclusivity on some of Lupin Limited's Diabetes products, its growth would have been 11.2% in the nine-month period. Excluding the impact of loss of exclusivity on Gibtulio® and Ajaduo®, Lupin Limited's Domestic growth was 11.2% year over year for nine months.
    Show source
    Excluding the impact of loss of exclusivity on products such as Gibtulio® and Ajaduo®, Domestic growth was 11.2% YoY for nine months.
  • Respiratory and Cardiovascular segments grew 1.6 times and 1.3 times IPM, respectively, during the nine-month period.
    Show source
    Key segments like Respiratory and Cardiovascular grew 1.6 times and 1.3 times IPM, respectively, during the nine-month period .
  • Other operating income was INR 67 crores in Q3 FY26, compared with INR 149 crores in Q3FY25 and INR 216 crores in Q2FY26, largely impacted by lower export benefits from the PLI scheme during the quarter.
    Show source
    Getting onto the P&L. Other Operating Income Other operating income for the quarter was at INR 67 crores as against INR 149 crores in Q3FY25 and INR 216 crores in Q2FY26, largely impacted by lower export benefits from the PLI scheme during the quarter .
  • R&D spend for the nine months FY26 was INR 1,555 crores, or 7.7% of sales.
    Show source
    For the nine months FY26, R&D spent at INR 1,555 crores is 7.7% of sales.
  • EBITDA was INR 5,988 crores for the nine-month period, an increase of 50% year over year, with margins of 29.8% compared with 24% over the same period last year. Lupin’s EBITDA in 9MFY26 was INR 59,885 Mn, or 29.8% of sales, up 50.3% year over year; EBITDA excludes Fx and Other income.
    Show source
    On a nine-month basis, EBITDA was INR 5,988 crores, an increase of 50% YoY with margins of 29.8% vis-a-vis 24% over the same period last year.
  • ETR was 21.4% for 9MFY26.
    Show source
    ETR Turning to the tax rate, ETR is 21.4% for the 9MFY26.
  • US business recorded its highest sales in the region in Q3 FY26, driven by Tolvaptan as the only generic on the market and base-business volume growth and seasonal tailwinds that more than offset low single-digit price erosion. Lupin Limited reported its highest ever quarterly sales in the US in Q3 FY2026, with double-digit growth in India and all other regions.
    Show source
    Turning to individual business segments, this quarter was a particularly strong one for us in the US., where we recorded the highest sales in the region so far.
  • Mirabegron license will be amortized over a period of time and will not impact EBITDA.
    Show source
    Page 9 of 18 February 13, 2026 Ramesh Swaminathan: It actually would not impact the EBITDA because it's actually a license that we need to kind of amortize over a period of time.
  • Emerging Markets turnover doubled because Dapagliflozin is a big hitter there.
    Show source
    Ramesh Swaminathan: It doubled in terms of turnover, given the fact that this product is big hitter out there.
  • Excluding the impact of loss of exclusivity on Gibtulio® and Ajaduo®, Lupin Limited's Domestic growth was 11.2% year over year for nine months. Replaced by a later filing.
  • Chronic share increased to 67% from 65% in Q2, and in-licensed products accounted for 6% compared with around 12% in FY25, which the company said would positively affect profitability going ahead. Replaced by a later filing.
  • Other Developed markets, including Europe, Canada and Australia, generated INR 812 crores in revenue, representing 11% year-over-year growth. Replaced by a later filing.
  • Chronic share has gone up to 67%. Replaced by a later filing.
  • The company continues to view Mirabegron as a very attractive contributor to its P&L. Replaced by a later filing.
    Show source
    And we still look at it as a very attractive contributor to our P&L .

Money and capital

  • Operating Working Capital was INR 7,948 crores as of 31st December, against INR 6,821 crores as of 31st March’25, equivalent to 101 days of working capital against 102 days in the previous quarter. Lupin Limited's Net Cash stood at INR 2,879 crores as of 31st December, against INR 310 crores as of 31st March 2025.
    Show source
    Net Cash Net Cash stood at INR 2,879 crores as against INR 310 crores as of 31 st March 2025.
  • USD 75 million balance payment for Mirabegron will be spread over to September '27.
    Show source
    The balance USD 75 million will be spread over to September '27.
  • The company has the ability to borrow about USD 1.5 billion–1.6 billion, apart from the cash on its balance sheet.
    Show source
    Ramesh Swaminathan: We have the ability to borrow about USD 1.5 billion - 1.6 billion, so to speak, apart from of course what we have on our balance sheet in terms of cash already.
  • Net Cash stood at INR 2,879 crores as of 31st December, against INR 310 crores as of 31st March 2025. Replaced by a later filing.

What it expects ahead

What management expects

  • Other Developed markets constitute around 11% of total sales, and their share is expected to increase with the anticipated closure of the VISUfarma acquisition during this quarter.
    Show source
    Other Developed markets constitute around 11% of our total sales and their share is expected to increase going ahead with the anticipated closure of the acquisition of VISUfarma during this quarter.
  • The company expects full-year EBITDA margins of 27% to 28%, higher than its earlier guidance of 25% to 26%.
    Show source
    We expect full-year EBITDA margins to be in the range of 27% to 28%, higher than our earlier guidance of 25% to 26%.
  • The company expects Mirabegron to be a material contributor in the next two years and hopes Tolvaptan will continue, given the product's size and its 35% share of that market; the company continues to build share on Tolvaptan.
    Show source
    Vinita Gupta: We're very pleased that we have Mirabegron as a material contributor in the next two years, as well as hopefully Tolvaptan also continues, just given the size of the product, and the share we have so far, maybe we have 35% share of that market, given that it's a specialty product.
  • The company plans to start its first 505(b)(2) in FY27, with 505(b)(2)s expected to ramp up in the next couple of years as a material contributor.
    Show source
    In fiscal year FY27, we will start our first 505(b)(2), and that's going to ramp up in the next couple of years as a material contributor as well.
  • The company expects its India business to grow 20% - 30% ahead of the market.
    Show source
    Nilesh Gupta: So, I think 20% - 30% ahead of the market is what we would see ourselves at.
  • R&D spending may increase as it focuses on a number of things; the company has been conservative in saying 24% to 25% would be par for the course given possible top-line product tapering and extra R&D expenditure.
    Show source
    So combined with the fact that there will be some tapering off of top-line products and the fact that you might have to provide for extra expenditure on the R&D, we’ve just been conservative in saying about 24% to 25% would be par for the course.
Show 32 more statements

What management expects

  • The company expects its injectables portfolio to reach USD 100 million plus in the next three years, with tens of millions of dollars in individual products, in addition to biosimilars.
    Show source
    We really see the injectables portfolio ramping up in the next three years to USD 100 million plus with tens of millions of dollars in individual products and then biosimilars adding to it.
  • Aspiration is to continue to grow its India Rx business at a double-digit rate; it believes the market will grow 7%–8%, and links its growth expectation to a focus on chronic therapy areas, which account for 65% of its revenues.
    Show source
    We believe that the market will grow 7% - 8%, and therefore we will grow double -digit in this segment.
  • The company would look at specialty assets for purchases, with a historical sweet spot of about USD 250 million–300 million that it might increase depending on the proposition.
    Show source
    Hither to, we have been looking at, in fact, something in the range of sweet spot about USD 250 million - 300 million.
  • The revenue is still on track at EUR 60 million plus.
    Show source
    And the revenue is still on track, I believe, EUR 60 million plus .
  • The company expects an increasing share of R&D investments to flow into specialty programs and value-added medicines, including long-acting injectables, green propellant-based products, and 505(b)(2)s.
    Show source
    Over time, we expect a growing share of R&D investment to flow into specialty programs and value -added medicines, including long -acting injectables, gre en propellant products and 505( b)(2) assets.
  • The company expects full-year R&D to be around 7.5% to 8.5%.
    Show source
    For the full year, as indicated, we expect R&D to be around 7.5% - 8.5% EBITDA EBITDA excluding Forex and other income during the quarter was INR 2,210 crores vis-a-vis INR 1,366 crores in the same period last year, an increase of 62% YoY with a margin of 31.1% vis-a-vis 24.3% last year in the same period, an increase of 681 basis points over the last year.
  • The company expects full-year ETR to be around 21% to 22%.
    Show source
    For the full year, we expect ETR to be about 21% - 22%.
  • The company expects EBITDA margins of around 24% - 25% next year, with some products sustaining momentum.
    Show source
    All of this would also help us to kind of maintain the gross margins and thereafter the EBITDA margins.
  • The company aims to double the share of complex products in its US business over the next few years.
    Show source
    As mentioned earlier, we remain focused on doubling the share of complex products in our US Business over the next few years, while continuing to expand our specialty portfolio through a mix of organic initiatives and targeted acquisitions.
  • Obesity division will engage diabetologists, cardiologists, and gastroenterologists ahead of the planned day one launch of injectable Semaglutide, while the company continues parallel development of the oral formulation.
    Show source
    This division will engage diabetologists, cardiologists, and gastroenterologists ahead of the planned day one launch of injectable Semaglutide, while we continue parallel development of the oral formulation.
  • The company expects its Other Developed markets contribution to increase as it rolls out a pipeline of complex products and completes the acquisition of VISUfarma, which it expects to close this quarter.
    Show source
    We expect this contribution to increase as we roll out a pipeline of complex products and complete the acquisition of V ISUfarma, which we expect to close this quarter.
  • The company expects overall margins in Q4 to be tempered by higher R&D expenditure and lower PLI income, despite expecting robust business performance.
    Show source
    Whilst we expect business to continue to exhibit robust performance, overall margins in Q4 would be tempered by higher R&D expenditure and a lower PLI income.
  • The company has multiple new product launches planned over the next couple of years, particularly in Injectables, Respiratory and Biosimilars.
    Show source
    Having said that we have multiple new product launches planned over the next couple of years.
  • US institutional business will be a material build over the next three years and is expected to ramp up over the next three to five years to become a material contributor to the US business.
    Show source
    And we see it really ramping up very nicely over the next three to five years to be a material contributor to the US business.
  • The company expects to launch Ranibizumab in FY27.
    Show source
    With Page 7 of 18 February 13, 2026 Pegfilgrastim, then Ranibizumab that we hopefully will be able to launch in FY27.
  • The company expects Aflibercept and Etanercept to launch in FY30.
    Show source
    Then the On-body Pegfilgrastim, which is making good progress , and then Aflibercept and Etanercept in CY29, that will be actually FY30.
  • The company expects its biosimilar business to become a material contributor to the US business.
    Show source
    Likewise, the biosimilar business in particular will also be a material contributor to the US.
  • The company expects to sustain revenue above a billion plus level over the next couple of years and build from there by bringing material biosimilars, respiratory products, injectables and other first to files to market.
    Show source
    So, we have multiple growth drivers at this point for the organization and feel fairly confident that we can one, sustain this billion plus revenue level over the next couple of years and build from there as we bring material biosimilars, respiratory products, as well as injectables, including the other first to files that we have in our portfolio to market.
  • The company is exclusive first to file on Xywav, with a launch date of FY29.
    Show source
    The launch date is FY29, if I'm not mistaken.
  • The insulin opportunity and Semaglutide are growth drivers for Lupin Limited in India.
    Show source
    So, lots of positive growth drivers for India.
  • The company expects Iron Sucrose to be a material injectable product.
    Show source
    We have Eribulin, a smaller product, just looking through the major products, Iron Sucrose will be a material one for us.
  • The company would launch Pegfilgrastim this quarter, with revenue numbers expected to start appearing in the next fiscal year.
    Show source
    Vinita Gupta: We would launch this quarter, but you'll start seeing numbers really in the next fiscal year.
  • R&D spending includes complex injectables, inhalations, drug-device combinations with clinical trials, and biosimilars; the spending would keep going up in absolute value terms, while it might stagnate at a particular point as a percentage of sales if turnover keeps going up.
    Show source
    But in absolute value terms, it would certainly keep going up.
  • The company is planning to bring NaMuscla® into the U.S. and would like to add other products in neurology.
    Show source
    We are planning to bring NaMuscla® into the U.S and would like to get other products in the therapy area.
  • The company would like to add ophthalmology assets in Europe and, ideally, in the U.S., Europe and Other Developed markets; it may start in Europe with VISUfarma.
    Show source
    And third now is ophthalmology, maybe have a start in Europe with VISUfarma, but we would like to get additional assets, both in Europe as well as ideally U.S, Europe and Other Developed markets.
  • The company is selectively pursuing biosimilar programs it believes can be in the first wave and where it can be one of few based on technology advantage or otherwise.
    Show source
    We are selectively going after programs that we believe we can be in the first wave.
  • The company is building a commercial front-end for three specialty therapy areas that it can leverage across biosimilars and branded specialty products, and is carving out a therapeutic-area strategy for biosimilars.
    Show source
    And third, we also have a lens of the three therapy areas that we want to build in the specialty front, because we also are building commercial front -end for the three areas that we can leverage across biosimilars as well as branded specialty products.
  • The company plans to file Nexplanon® in FY28; its development cycle is long and the development is complex.
    Show source
    Vinita Gupta: I believe it is planned to be filed in FY28.
  • The company expects double-digit growth in the market for the next couple of quarters and the next couple of years. Replaced by a later filing.
    Show source
    And I think not just for the next couple of quarters, but I think for the next couple of years we would expect to continue growth.
  • The company is looking at assets in Phase III or assets that have completed Phase II successfully and are ready to go into Phase III. Replaced by a later filing.
    Show source
    So, we are also looking at assets that are in Phase III or have completed Phase II successfully and are ready to go into Phase III .
  • The company has expanded into newer divisions and therapy areas, and expects more innovative products from its portfolio in the next three to four years. Replaced by a later filing.
    Show source
    In the next three - four years, you'll start seeing more innovative products coming from our portfolio as well.
  • The company would invest in adjacencies only up to the amount of the initial estimates. Replaced by a later filing.
    Show source
    So, we would then invest only as much as the initial estimates were.

What it is building and selling

Projects and capacity

  • The company has filed both the injectable generic version and a 505(b)(2) version of Dalbavancin.
    Show source
    Vinita Gupta: So apart from the products I mentioned, we also have Dalbavancin that we have filed, both the injectable, the generic version, as well as a 505(b)(2) version of the product.
  • The company is still developing Breo Ellipta and hopes to make material progress this calendar year.
    Show source
    We hope to really make material progress this calendar year.
  • Nexplanon® drug-device combination is in clinical development.
    Show source
    Vinita Gupta: It is in clinical development right now .
  • The company is adding more projects overall. Replaced by a later filing.
    Show source
    Vinita Gupta: So, it is adding more projects overall .

Demand and pricing

  • The company says competitors in Tolvaptan are likely to enter in a staggered manner; other competitors have November’26, 30 months stay date and into '27.
    Show source
    So we think that it, if competition comes in it's likely going to be staggered.

Segments

  • The company had over 50 active products in its pipeline, with near-term emphasis on Respiratory, Complex Injectables and Biosimilars.
    Show source
    We have over 50 active products in the pipeline, with nea r-term emphasis on Respiratory, Complex Injectables and B iosimilars.
Show 7 more statements

Segments

  • The company and Zydus have a 40% generic share between them and have 40% of the overall Mirabegron molecule.
    Show source
    Vinita Gupta: Well, so we have a 40% generic share between us and Zydus, we also have 40% of the overall molecule .
  • The company launched generic Risperdal Consta® with CGT exclusivity in Q3 FY26; it was the first product from its proprietary Nanomi long-acting injectable platform.
    Show source
    We also launched generic Risperdal Consta® with CGT exclusivity, first product from our proprietary Nanomi long-acting injectable platform.
  • The company launched two new divisions during the quarter, including one focused on obesity.
    Show source
    During the Page 2 of 18 February 13, 2026 quarter, we also launched two new divisions including one focused on obesity.
  • The company received approvals in the last couple of quarters for Glucagon, Liraglutide and Risperdal Consta® injectable products, and Pegfilgrastim approval enables it to enter the biosimilars market and build the institutional business.
    Show source
    So, as I look at the last couple of quarters, we've got approvals for injectable products like Glucagon, Liraglutide, Risperdal Consta®, and with the Pegfilgrastim approval getting into the biosimilars market as well, to build the institutional business.

Deals and partners

  • The company entered into a strategic partnership with Gan & Lee of China for Bofanglutide, a novel fortnightly GLP-1 agonist, strengthening its Diabetes and Obesity portfolio in India.
    Show source
    In addition, we entered into a strategic partnership with Gan & Lee of China for Bofanglutide, a novel fortnightly GLP-1 agonist, further strengthening our Diabetes and Obesity portfolio in India.
  • The company entered into an exclusive licensing agreement with Valorum to commercialize Pegfilgrastim, with an expected launch before the end of this quarter.
    Show source
    We have entered into an exclusive licensing agreement with Valorum to commercialize the product with an expected launch before the end of this quarter.
  • The company has tied up with a company with experts across the biosimilars market from McKesson, AmerisourceBergen and other specialty distribution groups.
    Show source
    We have tied up with this company with strong experts across the biosimilars market from the McKesson and AmerisourceBergen, other specialty distribution groups.

Risks, rules and outside factors

Risks and disputes

  • The Mirabegron settlement has given Lupin certainty, removed its litigation burden and risk, and left no impediment to selling the product in the marketplace.
    Show source
    We have no litigation burden anymore, no risk, and no impediment to sell the product in the marketplace.

Rules and policy

  • The company received NAI status with zero observations for its Nagpur Unit - 1 facility and EIRs for Nagpur Unit - 2 injectables and the Aurangabad facility.
    Show source
    On the compliance front, we received NAI status with zero observations for our Nagpur Unit - 1 facility along with EIRs for Nagpur Unit - 2 injectables and the Aurangabad facility.
  • The next Orange Book patent of Mirabegron expires in 2030.
    Show source
    Because the next Orange Book patent of Mirabegron expires only in 2030 .
  • Biologics facility in Pune successfully passed a US FDA inspection in Q3 FY26, followed by approval of Pegfilgrastim, its first biosimilar for the US market. Replaced by a later filing.

Everything else said on the call

Group structure

  • The company is looking at specialty assets in the U.S., Europe and other developed markets, including clinical-stage assets that will require investment before they are brought to market.
    Show source
    And as we mentioned earlier, we are looking at clinical stage assets, too, that will require investment before we bring it to the market.
  • The company expects to close the transaction in the next few weeks of this quarter and will start consolidating next quarter onwards. Replaced by a later filing.
    Show source
    Vinita Gupta: We expect to close it in the next few weeks of this quarter, basically.

Other

  • The company added 900 people to its salesforce in the last six months.
    Show source
    We had added 900 people to our salesforce in the last six months.
  • The company has achieved the highest A-leadership rating from CDP for climate change and water security.
    Show source
    ESG On the sustainability front, Lupin has achieved the highest A-leadership rating from CDP for both climate change and water security, placing us amongst the select group of global companies recognized for excellence in sustainability performance and transparency of disclosures.
  • Green-house gas emissions reduction targets have been formally approved by the SBTi.
    Show source
    In addition, Lupin's green-house gas emissions reduction targets have been formally approved by the SBTi, reinforcing the scientific rigor and credibility of our climate ambitions.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Nikhil Mathur: First and foremost, congrats on the continued great performance. My first question is on the US outlook, let's say, going into FY29 as well. Now, obviously, with the Mirabegron settlement, it seems that Mirabegron should continue into FY27 and certain part of FY28 as well. But can you highlight what will be the drivers of the US business once Tolvaptan and Mirabegron start tapering off? You have Pegfilgrastim approval, we have talked about other respiratory assets. So, any help on how should we look at meaningful launches over the next two years, so that once Mirabegron and Tolvaptan come off, and you go back to a growth part in the US any colour on this?

    Answer, vinita gupta

    Vinita Gupta: We're very pleased that we have Mirabegron as a material contributor in the next two years, as well as hopefully Tolvaptan also continues, just given the size of the product, and the share we have so far, maybe we have 35% share of that market, given that it's a specialty product. So, we continue to build share on Tolvaptan. Having said that we have multiple new product launches planned over the next couple of years. In particular, on the Injectables front, some on the Respiratory front as well as the Biosimilars front. So, as I look at the last couple of quarters, we've got approvals for injectable products like Glucagon, Liraglutide, Risperdal Consta®, and with the Pegfilgrastim approval getting into the biosimilars market as well, to build the institutional business. The institutional business will be a material build over the next three years. And we see it really ramping up very nicely over the next three to five years to be a material contributor to the US business.

    Answer, vinita gupta

    Likewise, the biosimilar business in particular will also be a material contributor to the US. With Page 7 of 18 February 13, 2026 Pegfilgrastim, then Ranibizumab that we hopefully will be able to launch in FY27. Then the On-body Pegfilgrastim, which is making good progress , and then Aflibercept and Etanercept in CY29, that will be actually FY30. We have other products that we have planned as well, like Mepolizumab, that are in the pipeline. So pretty rich pipeline of biosimilars that we believe given the current momentum in the marketplace, access into the market will be a material growth driver for the organization. Additional growth driver, which so far has not featured into our business is 505(b)(2)s. The company has been working on 505(b)(2)s for the past couple of years, especially on the injectable front. In fiscal year FY27, we will start our first 505(b)(2), and that's going to ramp up in the next couple of years as a material contributor as well.

    Answer, vinita gupta

    So, we have multiple growth drivers at this point for the organization and feel fairly confident that we can one, sustain this billion plus revenue level over the next couple of years and build from there as we bring material biosimilars, respiratory products, as well as injectables, including the other first to files that we have in our portfolio to market.

  2. Question

    Nikhil Mathur: You have tentative approval for this product, Xywav . I guess the litigation is ongoing. Any probabilistic launch timing of this product? And I suppose Lupin could be sole FTF in this product?

    Answer, vinita gupta

    Vinita Gupta: Yes. We are exclusive first to file on that product . The launch date is FY29, if I'm not mistaken.

  3. Question

    Nikhil Mathur: One final question I have on the India business. I think the Jan IQVIA data is showing good growth. Also, last quarter, ex - tender business, I think the growth has come in good. So, are we in a good, 12%-13% growth environment for the company? And with all the IL issues in the base now, and insulin tailwinds?

    Answer, nilesh gupta

    Nilesh Gupta: So, I think 20% - 30% ahead of the market is what we would see ourselves at. The market is growing strong, so double-digit growth is assured. And I think not just for the next couple of quarters, but I think for the next couple of years we would expect to continue growth. I think a lot of the exclusivities are behind us. The insulin opportunity is there. Semaglutide will come in as well . So, lots of positive growth drivers for India.

  4. Question

    Tushar Manudhane: On your comments on use of AI, if you could elaborate which geography or which divisions have started implementing the use of AI and how fast or Page 8 of 18 February 13, 2026 difficult whichever way, the use of AI has been on the development side, on the manufacturing side?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: We have made some good progress on AI, and this is across the entire company. We started off with sales and marketing but clearly, we are looking at other divisions also. Manufacturing and maintenance is one such case. The other is of course quality. We’re working with multiple consultants. The first most important thing is the fact that we need to bring all of this data together. Over time we've actually created several repositories and it's important to bring everything together under one architectural roof.

    Answer, ramesh swaminathan

    That's exactly what we're trying to do at this stage. We have set our eyes on AI for all our functions including finance, HR, legal and procurement and we expect a lot of these pilot projects that we 've been working on to be implemented over the next nine months to twelve months .

  5. Question

    Tushar Manudhane: Secondly, the opening remarks also alluded to forming a new division for Semaglutide with respect to catering to diabetologists, cardiologists, gastroenterologists . So how many MRs, is sort of getting focused for this particular product?

    Answer, nilesh gupta

    Nilesh Gupta: It's about 200 people but I think we'll scale it up as needed .

  6. Question

    Tushar Manudhane: How do you see this because given that there are going to be multiple players, there will be a pricing impact but volumes scaling up again how the demand is expected to shape up that is something really interesting to watch out. But if you could throw your insights on this opportunity for India?

    Answer, nilesh gupta

    Nilesh Gupta: I think many companies are going to launch it. But the fact that we are a large Cardio - Metabolic player will make sure that we are able to get the right kind of prescription share in this product. There's a lot planned. Again, what we're saying is not unique, everybody else is planning extra bells and whistles from that perspective. But I think we have a very deep patient support program that we intend to engage into this as well. We believe that we'll be there on day one. And again, as a large Cardio - Metabolic player, it should be a nice opportunity.

    Answer, nilesh gupta

    While we've created this division, we have the ability to scale up, we have the ability to add it into other divisions as well. So, I think it would be interesting. I think it's just a month away.

  7. Question

    Bino Pathiparampil: Just a follow up on Mirabegron settlement. From your notes, I see that you have taken a provision of USD 15 million, whereas the total pay-out is USD 90 million. So why only USD 15 million provision?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: Yes. USD 15 million is essentially what relates to the past, whilst USD 75 million is linked to, in fact, the future and we being in the market that's the reason why it’s only USD 15 million at this stage. The balance USD 75 million will be spread over to September '27. Bino Pathiparampi l: So that will come in other expenses later on in quarters ? Page 9 of 18 February 13, 2026 Ramesh Swaminathan: It actually would not impact the EBITDA because it's actually a license that we need to kind of amortize over a period of time.

    Answer, ramesh swaminathan

    Bino Pathiparampi l: Now that we have a license in place, is there room to improve our Mirabegron market share? Because I believe we were selling much lower quantity than the other generic competitor. Is there a chance to equalize this ?

    Answer, vinita gupta

    Vinita Gupta: Well, so we have a 40% generic share between us and Zydus, we also have 40% of the overall molecule . So, we'll see what makes sense. It's a really good contributor to our P&L and we'll determine if it makes sense to take on additional share. Bino Pathiparampi l: Why this end date of September'27? Because the next Orange Book patent of Mirabegron expires only in 2030 . So, what prevents you from being exclusive in the market till then?

    Answer, vinita gupta

    Vinita Gupta: We believe majority of the settlements that the brand has entered with other companies are till September '27.

  8. Question

    Bino Pathiparampil: Last question on Tolvaptan. How do you see the competitive scenario panning out? Why hasn't Apotex launched till now and do you expect more approvals?

    Answer, vinita gupta

    Vinita Gupta: We're not certain why they haven't launched. We know that IP is certainly a hurdle that we have crossed and the others haven't. So that could be a consideration. It's not the easiest product to manufacture. That could be another consideration. We don't have any intelligence on Teva's approval and then we know that other competitors have November’26, 30 months stay date and into '27. So we think that it, if competition comes in it's likely going to be staggered.

  9. Question

    Bino Pathiparampil: Any update on Breo Ellipta in your pipeline?

    Answer, vinita gupta

    Vinita Gupta: We're still making progress with the development we were hoping to have it filed by now, but I'd say that it's still actively in our Respiratory pipeline. We hope to really make material progress this calendar year.

  10. Question

    Kunal Dhamesha: So basically, the prepaid per unit licensing fee , how will we account for that? Will it be offset from the revenue or will it be recognized in COGS? Or how to think about that?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: There are two portions as we were just mentioning . There is a smaller portion which must be knocked off from the overall operating profit, and there's an element which will get amortized over a period. So, both will actually hit the P&L. Kunal Dhamesha: Okay. One above EBITDA, one below EBITDA ? Page 10 of 18 February 13, 2026 Ramesh Swaminathan: Yes.

Show 16 more questions
  1. Question

    Kunal Dhamesha: And second question on the overall profitability outlook, let's say, beyond FY26. I think earlier we had suggested for FY27 EBITDA margin range of around 24% to 25%. So, how do we think that is going to play out now with the kind of products that we have in U.S and India, etcetera.

    Answer, ramesh swaminathan

    Ramesh Swaminathan: Clearly the top-line buoyancy would continue, and we just mentioned about the fact that Mirabegron will have a fresh lease of life. Tolvaptan, we are not seeing competition, though, we do expect some to enter at some point of time. And Vinita alluded to a number of new product launches that could potentially happen next year, and there's Semaglutide opportunity, and of course, there are opportunities in Emerging Markets. So clearly, we are very bullish about, in fact, keeping the top-line buoyancy going. There is tremendous focus on costs as well, there are a number of initiatives that we've taken up in recent times. All of this would also help us to kind of maintain the gross margins and thereafter the EBITDA margins. Whilst there would be a dip in terms of margins vis-a-vis the current year because of sheer competition for some of the products, we still believe that we would be good for looking at 24% - 25% next year.

  2. Question

    Kunal Dhamesha: And last one for Nilesh sir on the Semaglutide generic launch. What is your expectation, let's say, from a year one market perspective, how much it can grow? And did we allude to potential revenue size in year one in one of the media interviews, if I heard it correctly?

    Answer, nilesh gupta

    Nilesh Gupta: Yes, we did. I think the internal modelling that we have at this point of time seems to suggest that this will be a INR 1,500 crore odd opportunity in the first year, and we talked about maybe doing INR 50 - 60 crores something like that in the first year. But we'll see. I think there's just too many variables right now, how much is the pricing going to go down, how much is the pent-up demand. I mean, you've seen how Mounjaro went in the first five months since launch, right, so when this happens, the price point, what it means. And we want to be responsible; we want to do this the right way. We don't want to just sell this for the heck of it.

  3. Question

    What should be the R&D incr ease or investments in other areas that you're looking at?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: There is a lot of focus on costs, and whilst that will certainly continue , there would also be spends for R&D, which may increase, given the fact that we are focusing on a number of things out there. So combined with the fact that there will be some tapering off of top-line products and the fact that you might have to provide for extra expenditure on the R&D, we’ve just been conservative in saying about 24% to 25% would be par for the course.

  4. Question

    It is great to have products like Glucagon and Risperdal Consta®, Victoza® approvals and having been launched. But I mean, none of these products would be big enough to kind of move the needle so much as far as the overall injectable sales is concerned . So, how far are we from a big material launch on the injectable side? Can you talk about what products have been filed? What are you looking at? And which sort of products can give you, let's say, USD 100 million - 200 million kind of a sales base on the injectables? And over what time period can you achieve that?

    Answer, vinita gupta

    Vinita Gupta: So apart from the products I mentioned, we also have Dalbavancin that we have filed, both the injectable, the generic version, as well as a 505(b)(2) version of the product. We have Eribulin, a smaller product, just looking through the major products, Iron Sucrose will be a material one for us. And more 505(b)(2)s that we haven't announced. We really see the injectables portfolio ramping up in the next three years to USD 100 million plus with tens of millions of dollars in individual products and then biosimilars adding to it.

  5. Question

    Nikhil Mathur: And on Pegfilgrastim, while it's great to have the approval in place, but can it be a meaningful revenue driver because there is competition there. I mean, some of the biosimilars are well -established for a number of years now. So, what's the go-to-market strategy on Pegfilgrastim? And when do we start numbers showing up for Lupin in this product ?

    Answer, vinita gupta

    Vinita Gupta: We would launch this quarter, but you'll start seeing numbers really in the next fiscal year. And we are very encouraged with what we are hearing from the marketplace. We have tied up with this company with strong experts across the biosimilars market from the McKesson and AmerisourceBergen, other specialty distribution groups. And we see a real place for a new Pegfilgrastim in the marketplace. I'd say a couple of years ago, we were not very gung-ho on biosimilars, but today we see significant potential wit h Pegfilgrastim to start with, but also the other biosimilars that we have in our pipeline. Nikhil Mathur : With so many biosimilars and this product being already there, why would a ABC or a McKesson tie -up with Lupin? I mean, is the cost going to be the proposition here?

  6. Question

    In the last couple of years, your R&D budget has gone from around INR 1,400 crores - 1,500 crores to around almost INR 2,100 crores now. So, if you would like to share which area that you're spending in, how much of this would be on biosimilars that you have budgeted? Because some of these spend s would come up also in the years ahead. So, is there a chance that maybe after FY26 or FY27, your R&D starts going down also?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: No, I wouldn't think so. We are spending on the more complex stuff, which includes the injectables piece, the inhalations piece, any drug device combination always costs a lot of money with clinical trials. And of course we have biosimilars. We've also always spoken about specialty ambitions. So , the spends would keep going up but if a turnover keeps going up also, as a percentage of sales, it might stagnate at a particular point. But in absolute value terms, it would certainly keep going up.

  7. Question

    Kunal Randeria: If I understand correctly, you're not adding more projects, it's just that you're expanding into a bit more -high value, high-cost projects?

    Answer, vinita gupta

    Vinita Gupta: So, it is adding more projects overall .

  8. Question

    Kunal Randeria: Second question, you have now a healthy cash balance, you are generating cash. So, is specialty on your radar? And exactly which therapies in which markets would you be targeting?

    Answer, vinita gupta

    Vinita Gupta: So, it has been on our radar, as we have shared in the past. And the therapy areas also, we've been pretty vocal. The respiratory being an area that we would like to build given our current position. As well as neurology, where we have NaMuscla® to start with. We are planning to bring NaMuscla® into the U.S and would like to get other products in the therapy area. And third now is ophthalmology, maybe have a start in Europe with VISUfarma, but we would like to get additional assets, both in Europe as well as ideally U.S, Europe and Other Developed markets.

  9. Question

    Kunal Randeria: Would you be more comfortable buying assets, which have been approved? Or ones where you perhaps have to do a Phase III trial, file it and then commercialize it?

    Answer, vinita gupta

    Vinita Gupta: We've been looking across the board. Of course, commercialized assets would be very lucrative, but they are far and few, because companies don't part with them easily. So, we are also looking at assets that are in Phase III or have completed Phase II successfully and are ready to go into Phase III .

  10. Question

    Bansi Desai: The first question is on the overall biosimilar landscape in the U.S. We see recent developments, which are all aimed at improving affordability and accessibility, which is good, structurally positive for us as well. But at the same time, it is also going to make market more competitive. So, how should we think about what will be those key factors which will determine our success? You mentioned about having that cost advantage, but I'm assuming a lot of Indian companies would have that. So that's number one. And the second is we also see PBMs having their own brands or bringing their own labels in the space. That adds to the competition, right? How do you think about that relati

    Answer, vinita gupta

    So, we are very selective in our portfolio shortlist, in our selection process of our pipeline. We are selectively going after programs that we believe we can be in the first wave. We believe we can be one of few based on technology advantage or otherwise . And third, we also have a lens of the three therapy areas that we want to build in the specialty front, because we also are building commercial front -end for the three areas that we can leverage across biosimilars as well as branded specialty products. So, we're kind of carving our own therapeutic area strategy as well on the biosimilars front. All of those give us the confidence that we we're not going after everything under the sun, from a portfolio standpoint, we're being very selective around areas whe re we can truly make a difference. The other thing I will say is, while you hear about the cost advantage of India across the generic drug companies, just look at how many biosimilars companies are out there.

  11. Question

    Bansi Desai: And just a second question, which is a clarification on Mirabegron. If I think about USD 90 million of payment, is it more or less what we have earned so far on this product or much lower than what we'd have made? That's number one. Second, with the settlement until September '27, does it mean that we should not anticipate any generic players to come in this period, or they could come and settle with similar terms, that is paying royalty, etcetera, on the sales that they could do?

    Answer, vinita gupta

    Vinita Gupta: It's hard to predict what other generics will do. For us, it's given us certainty . We have no litigation burden anymore, no risk, and no impediment to sell the product in the marketplace. And we still look at it as a very attractive contributor to our P&L .

  12. Question

    Vivek Agrawal: A couple of years back, you highlighted that you are developing a product, it's a drug-device combination called Nexplanon ®. So just want to understand where the product is. Is it still in the development? Or have you filed this product? Any status regarding this product ?

    Answer, vinita gupta

    Vinita Gupta: It is in clinical development right now .

  13. Question

    Vivek Agrawal: But don't you think that's quite long that it’s still there in the clinical development? So, when you expect to file this product?

    Answer, vinita gupta

    Vinita Gupta: I believe it is planned to be filed in FY28. It is a long development cycle, also pretty complex development.

  14. Question

    Vivek Agrawal: And second question is related to India business where I think you have done the business quite well in the last couple of years and Rx business is doing phenomenally well, right, and the confidence is also there. Just to understand like the next three to four years, how to look at the growth trends of India Rx business? And if you can outline, for example, the kind of initiatives that you are taking in terms of product launches, in terms of market penetration, salesforce, etcetera, so that w hat gives you the confidence that you could continue to grow this business ?

    Answer, nilesh gupta

    Nilesh Gupta: So, our aspiration would be to continue to grow double -digit. We believe that the market will grow 7% - 8%, and therefore we will grow double -digit in this segment. That is linked with the fact that our focus is on chronic therapy areas. As you know, 65% of our revenues come from chronic side. We're doubling down. We had added 900 people to our salesforce in the last six months. So, we're doubling down on the market .

    Answer, nilesh gupta

    We have expanded into newer divisions, into newer therapy areas as well, and we haven't even done the innovation pipeline yet. I think that's something which has just started. In the next three - four years, you'll start seeing more innovative products coming from our portfolio as well. So, I think Page 16 of 18 February 13, 2026 a combination of the need for the market, expanding our reach, expanding the breadth of our offering as well. All these together will drive it. We've talked in the past about other things like patient support . I think all of these together will help deliver this growth.

  15. Question

    Vivek Agrawal: In terms of capital allocation, right, apart from R&D investments that you are making, and you are generating significant cash. So, if you can prioritize, let's say, a couple of, I think, top three areas where you want to spend money, in the next three to four years ?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: We have the ability to borrow about USD 1.5 billion - 1.6 billion, so to speak, apart from of course what we have on our balance sheet in terms of cash already. From a purchase perspective, we would be looking at specialty assets. Hither to, we have been looking at, in fact, something in the range of sweet spot about USD 250 million - 300 million. We might up it a little more based again on the proposition on the table. So that's the most important part for us. We have also defined the threshold limits when it comes to in fact the adjacencies and so on. So, we would then invest only as much as the initial estimates were.

  16. Question

    Vivek Agrawal: So, when you talk about specialty assets, right, is it mainly related to U.S? Or are you also comfortable buying some assets, for example, which might be making losses initially and can turn profitable over a period of time?

    Answer, vinita gupta

    Vinita Gupta: We are looking at U.S, Europe, Developed markets, like the VISUfarma was Europe, right, and U.S. as well. And as we mentioned earlier, we are looking at clinical stage assets, too, that will require investment before we bring it to the market.

    Answer, vinita gupta

    Vinita Gupta: We expect to close it in the next few weeks of this quarter, basically. So, we'll start consolidating next quarter onwards. And the revenue is still on track, I believe, EUR 60 million plus .

    Answer, vinita gupta

    Vinita Gupta: But 25% to start. Shyam Srinivasan : Second question on Emerging Markets. Is there a base effect or we had like 40% plus growth. Any geographies to call out?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: Thanks to Dapagliflozin that we introduced out there, and of course, the lineup that we have for the future will kind of continue for some time . Shyam Srinivasan : Maybe constant currency growth, like 40% seems odd. So, is it like local currencies? What are these growing at?

    Answer, ramesh swaminathan

    Ramesh Swaminathan: It doubled in terms of turnover, given the fact that this product is big hitter out there. Shyam Srinivasan : And lastly, on India growth, I know the 5.6% volume growth is nine months. So, what's the 11%?

    Answer, vinita gupta

    Vinita Gupta: Actually, the share of chronic has gone up to 67%.

    Answer, vinita gupta

    Vinita Gupta: Thank you all. Hopefully we were able to respond to all your questions. We are very optimistic at this point to close the year on a very strong note, and equally the year ahead looks pretty strong. We continue to work around our strategic growth drivers to build up specialty and complex platforms to enable us to grow sustainably over the next few years . So, thank you again for joining us, and we look forward to interacting with you in the next couple of months.

Questions about this call

When was the Lupin Q3 FY26 earnings call transcript filed?
Lupin filed the transcript with the exchange on 17 Feb 2026. This page is built from that transcript.
What does this page list?
87 statements from the transcript across 11 topics, 45 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 26 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Lupin Q3 FY26 concall: what the company said · DalalOS